Literatur
-
1
A predictive model for
aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s
Lymphoma Prognostic Factors Project.
N Engl J Med.
1993;
329
987-994
-
2
Bonnet C, Fillet G, Mounier N. et
al .
CHOP alone compared with CHOP plus radiotherapy
for localized aggressive lymphoma in elderly patients.
J
Clin Oncol.
2007;
25
787-792
-
3
Bookman M A, Lardelli P, Jaffe E S, Duffey P L, Longo D L.
Lymphocytic lymphoma of intermediate differentiation:
morphologic, immunophenotypic, and prognostic factors.
J
Natl Cancer Inst.
1990;
82
742-748
-
4
Brenner D J, Hall E J.
Computed tomography – an
increasing source of radiation exposure.
N Engl J Med.
2007;
357
2277-2284
-
5
Coiffier B, Lepage E, Briere J. et al .
CHOP chemotherapy plus rituximab compared
with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
N Engl J Med.
2002;
346
235-242
-
6
Colwill R, Crump M, Couture F. et
al .
Mini-BEAM as salvage therapy for relapsed or refractory
Hodgkin’s disease before intensive therapy and autologous
bone marrow transplantation.
J Clin Oncol.
1995;
13
396-402
-
7
Dreyling M, Lenz G, Hoster E. et
al .
Early consolidation by myeloablative radiochemotherapy
followed by autologous stem cell transplantation in first remission
significantly prolongs progression-free survival in mantle-cell lymphoma:
results of a prospective randomized trial of the European MCL Network.
Blood.
2005;
105
2677-2684
-
8
Dreyling M. on behalf of the EGWG .
Newly diagnosed and relapsed
follicular lymphoma: ESMO Clinical Recommendations for diagnosis,
treatment and follow-up.
Ann Oncol.
2008;
19
ii77-78
-
9
El Gnaoui T, Dupuis J, Belhadj K. et al .
Rituximab, gemcitabine and oxaliplatin:
an effective salvage regimen for patients with relapsed or refractory
B-cell lymphoma not candidates for high-dose therapy.
Ann
Oncol.
2007;
18
1363-1368
-
10
Elis A, Blickstein D, Klein O. et al .
Detection of relapse in non-Hodgkin’s
lymphoma: role of routine follow-up studies.
Am J Hematol.
2002;
69
41-44
-
11
Fischbach W, Dragosics B, Kolve-Goebeler M E. et al .
Primary gastric B-cell lymphoma:
results of a prospective multicenter study. The German-Austrian
Gastrointestinal Lymphoma Study Group.
Gastroenterology.
2000;
119
1191-1202
-
12
Fischbach W, Goebeler M E, Ruskone-Fourmestraux A. et al .
Most patients with minimal
histological residuals of gastric MALT lymphoma after successful
eradication of Helicobacter pylori can be managed safely by a watch
and wait strategy: experience from a large international series.
Gut.
2007;
56
1685-1687
-
13
Forstpointner R, Dreyling M, Repp R. et al .
The addition of rituximab to a combination
of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly
increases the response rate and prolongs survival as compared with
FCM alone in patients with relapsed and refractory follicular and mantle
cell lymphomas.
Blood.
2004;
104
3064-3071
-
14 Forstpointner R, Unterhalt M, Dreyling M. et al .Maintenance therapy with rituximab leads
to a significant prolongation of response duration after salvage
therapy with a combination of rituximab, fludarabine, cyclophosphamide
and mitoxantrone (R-FCM) in patients with relapsed and refractory
follicular and mantle cell lymphomas. Blood 2006 108: 4003-4008
-
15 Fridrik M A, Hausmaninger H, Lang A. et al .Low risk patients with aggressive non-Hodgkin’s
lymphoma have superior suvival with dose density chemotherapy. ASCO Annual Meeting 2003 abstract 2306
-
16
Gallamini A, Stelitano C, Calvi R. et al .
Peripheral T-cell lymphoma unspecified
(PTCL-U): a new prognostic model from a retrospective multicentric clinical
study.
Blood.
2004;
103
2474-2479
-
17
Geisler C H, Elonen E, Kolstad A. et al .
Mantle cell lymphoma can be cured by intensive
immunochemotherapy with in-vivo purged stem-cell support. Final
Report of the Nordic Lymphoma Group MCL2 Study.
ASH Annual Meeting
Abstracts.
2007;
110
LB1
-
18
Guppy A E, Tebbutt N C, Norman A, Cunningham D.
The role of surveillance CT
scans in patients with diffuse large B-cell non-Hodgkin’s
lymphoma.
Leuk Lymphoma.
2003;
44
123-125
-
19
Haas R LM, Poortmans P, de Jong D. et al .
High response rates and lasting remissions
after low-dose involved field radiotherapy in indolent lymphomas.
J Clin Oncol.
2003;
21
2474-2480
-
20 Habermann T M, Weller E A, Morrison V A. et al .Rituximab-CHOP
versus CHOP alone or with maintenance rituximab in older patients
with diffuse large B-cell lymphoma. J Clin Oncol 2006 JCO.2005.2005.1003
-
21
Hagenbeek A, Bischof-Delaloye A, Radford J A. et al .
90Y-Ibritumomab Tiuxetan
(Zevalin(R)) Consolidation of first remission in advanced stage
follicular non-Hodgkin’s lymphoma: First results of the
International Randomized Phase 3 First-Line Indolent Trial (FIT)
in 414 patients.
ASH Annual Meeting Abstracts.
2007;
110
643
-
22
Harris N L, Jaffe E S, Diebold J. et al .
World Health Organization Classification of
Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report
of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November
1997.
J Clin Oncol.
1999;
17
3835-3849
-
23
Hiddemann W, Kneba M, Dreyling M. et al .
Frontline therapy with rituximab added
to the combination of cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP) significantly improves the outcome for patients
with advanced-stage follicular lymphoma compared with therapy with
CHOP alone.
Blood.
2005;
106
3725-3732
-
24
Horning S J, Rosenberg S A.
The natural
history of initially untreated low-grade non-Hodgkin’s
lymphomas.
N Engl J Med.
1984;
311
1471-1475
-
25
Hoster E, Dreyling M, Klapper W. et al .
A new prognostic index (MIPI) for patients
with advanced-stage mantle cell lymphoma.
Blood.
2008;
111
558-565
-
26
Kaufmann H, Raderer M, Wohrer S. et al .
Antitumor activity of rituximab plus thalidomide
in patients with relapsed/refractory mantle cell lymphoma.
Blood.
2004;
104
2269-2271
-
27
Kewalramani T, Zelenetz A D. et al .
Rituximab
and ICE as second-line therapy before autologous stem cell transplantation
for relapsed or primary refractory diffuse large B-cell lymphoma.
Blood.
2004;
103
3684-3688
-
28
Le Gouill S, Milpied N, Buzyn A. et al .
Graft-versus-lymphoma effect for aggressive
T-cell lymphomas in adults.
J Clin Oncol.
2008;
26
2264-2271
-
29
Leitch H A, Gascoyne R D, Chhanabhai M. et al .
Limited-stage mantle-cell lymphoma.
Ann Oncol.
2003;
14
1555-1561
-
30
Liedtke M, Hamlin P A, Moskowitz C H, Zelenetz A D.
Surveillance
imaging during remission identifies a group of patients with more
favorable aggressive NHL at time of relapse.
Ann Oncol.
2006;
17
909-913
-
31
Mac Manus M P, Hoppe R T.
Is radiotherapy
curative for stage I and II low-grade follicular lymphoma? .
J
Clin Oncol.
1996;
14
1282-1290
-
32
Marcus R, Imrie K, Belch A. et
al .
CVP chemotherapy plus rituximab compared with CVP
as first-line treatment for advanced follicular lymphoma.
Blood.
2005;
105
1417-1423
-
33
McKelvey E M, Gottlieb J A, Wilson H E. et al .
Hydroxyldaunomycin (Adriamycin)
combination chemotherapy in malignant lymphoma.
Cancer.
1976;
38
1484-1493
-
34
Meusers P, Engelhard M, Bartels H. et al .
Multicentre randomized therapeutic trial
for advanced centrocytic lymphoma: anthracycline does not improve
the prognosis.
Hematol Oncol.
1989;
7
365-380
-
35
Miller T P, Dahlberg S, Cassady J R. et al .
Chemotherapy alone compared with chemotherapy
plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s
lymphoma.
N Engl J Med.
1998;
339
21-26
-
36
Moskowitz C H, Bertino J R, Glassman J R. et al .
Ifosfamide, carboplatin,
and etoposide: a highly effective cytoreduction and peripheral-blood
progenitor-cell mobilization regimen for transplant-eligible patients
with non-Hodgkin’s lymphoma.
J Clin Oncol.
1999;
17
3776-3785
-
37
Neubauer A, Thiede C, Morgner A. et al .
Cure of Helicobacter pylori infection and
duration of remission of low-grade gastric mucosa-associated lymphoid
tissue lymphoma.
J Natl Cancer Inst.
1997;
89
1350-1355
-
38
Pfreundschuh M, Trumper L, Kloess M. et al .
Two-weekly or 3-weekly CHOP chemotherapy
with or without etoposide for the treatment of elderly patients
with aggressive lymphomas.
Blood.
2004;
104
634-641
-
39
Pfreundschuh M, Trumper L, Osterborg A. et al .
CHOP-like chemotherapy plus rituximab versus
CHOP-like chemotherapy alone in young patients with good-prognosis
diffuse large-B-cell lymphoma.
Lancet Oncol.
2006;
7
379-391
-
40
Philip T, Guglielmi C, Hagenbeek A. et al .
Autologous bone marrow transplantation
as compared with salvage chemotherapy in relapses of chemotherapy-sensitive
non-Hodgkin’s lymphoma.
N Engl J Med.
1995;
333
1540-1545
-
41
Reyes F, Lepage E, Ganem G. et
al .
ACVBP versus CHOP plus radiotherapy for localized
aggressive lymphoma.
N Engl J Med.
2005;
352
1197-1205
-
42
Rohatiner A ZS, Gregory W M. et al .
Meta-analysis
to evaluate the role of interferon in follicular lymphoma.
J
Clin Oncol.
2005;
23
2215-2223
-
43
Romaguera J E, Fayad L, Rodriguez M A. et al .
High rate of durable remissions after treatment
of newly diagnosed aggressive mantle-cell lymphoma with rituximab
plus hyper-CVAD alternating with rituximab plus high-dose methotrexate
and cytarabine.
J Clin Oncol.
2005;
23
7013-7023
-
44
Rummel M J, von Gruenhagen U, Niederle N. et al .
Bendamustine plus rituximab versus CHOP
plus rituximab in the first-line treatment of patients with indolent
and mantle cell lymphomas – first interim results of a
randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany).
ASH Annual Meeting Abstracts.
2007;
110
385
-
45 Savage K J, Harris N L, Vose J M. et al .ALK-negative anaplastic
large-cell lymphoma (ALCL) is clinically and immunophenotypically
different from both ALK-positive ALCL and peripheral T-cell lymphoma,
not otherwise specified: report from the International Peripheral
T-Cell Lymphoma Project. Blood 2008 111: 5496-5504
-
46
Schechter N R, Portlock C S, Yahalom J.
Treatment of mucosa-associated lymphoid tissue lymphoma of the
stomach with radiation alone.
J Clin Oncol.
1998;
16
1916-1921
-
47
Schouten H C, Qian W, Kvaloy S. et
al .
High-dose therapy improves progression-free survival
and survival in relapsed follicular non-Hodgkin’s lymphoma.
J Clin Oncol.
2003;
21
3918-3927
-
48
Schulz H, Bohlius J F, Trelle S. et al .
Immunochemotherapy with rituximab and overall
survival in patients with indolent or mantle cell lymphoma.
J Natl
Cancer Inst.
2007;
99
706-714
-
49
Smith M R, Zhang L, Gordon L I. et al .
Phase II study of R-CHOP followed by 90Y-Ibritumomab
Tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative
Oncology Group Study E1499.
ASH Annual Meeting Abstracts.
2007;
110
389
-
50
Solal-Celigny P, Roy P, Colombat P. et al .
Follicular lymphoma international prognostic
index.
Blood.
2004;
104
1258-1265
-
51
The Non-Hodgkin’s Lymphoma
Classification P. A clinical evaluation of the International Lymphoma
Study Group classification of non-Hodgkin’s lymphoma.
Blood.
1997;
89
3909-3918
-
52
Tilly H, Dreyling M. on behalf of the EGWG .
Diffuse large B-cell non-Hodgkin’s lymphoma.
Ann
Oncol.
2008;
19
ii67-69
-
53
Tilly H, Lepage E, Coiffier B. et
al .
Intensive conventional chemotherapy (ACVBP regimen)
compared with standard CHOP for poor-prognosis aggressive non-Hodgkin
lymphoma.
Blood.
2003;
102
4284-4289
-
54
Velasquez W S, Cabanillas F, Salvador P. et al .
Effective salvage therapy for lymphoma
with cisplatin in combination with high-dose Ara-C and dexamethasone
(DHAP).
Blood.
1988;
71
117-122
-
55
Witzig T E, Gordon L I, Cabanillas F. et al .
Randomized controlled trial of yttrium-90-labeled
ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy
for patients with relapsed or refractory low-grade, follicular,
or transformed B-cell non-Hodgkin’s lymphoma.
J
Clin Oncol.
2002;
20
2453-2463
-
56
You J Y, Chi K H, Yang M H. et al .
Radiation therapy versus
chemotherapy as initial treatment for localized nasal natural killer
(NK)/T-cell lymphoma.
Ann Oncol.
2004;
15
618-625
Prim. Univ. Doz. Dr. Michael A. Fridrik
Innere Medizin
3, Zentrum für Hämatologie und Medizinische
Onkologie, Allgemeines Krankenhaus Linz
Krankenhausstraße
9
A-4021 Linz
Phone: +43732/7806-1610
Fax: +43732/7806-1940
Email: michael.fridrik@akh.linz.at
